Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 2/20 | 0.49 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.49 |
| ▸ | ACP3 | P15309 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1576808 | 1.00 | PDCD1 (0.49) | PDCD1CD274ACP3EPHX1CYP1A2 | |
| SCHEMBL5653982 | 1.00 | PDCD1 (0.49) | PDCD1CD274ACP3EPHX1CYP1A2 | |
| SCHEMBL15669228 | 0.86 | TLR2 (0.43) | ACP3ALDH1A1RAB9A | |
| SCHEMBL15669229 | 0.86 | TLR2 (0.43) | ACP3ALDH1A1RAB9A | |
| SCHEMBL1070410 | 0.86 | BCHE (0.54) | — | |
| SCHEMBL7394895 | 0.86 | BCHE (0.54) | — | |
| SCHEMBL7396992 | 0.86 | BCHE (0.54) | — | |
| Hydrazine SCHEMBL28609493 | 0.86 | PDCD1 (0.51) | PDCD1CD274ALDH1A1RAB9A | |
| SCHEMBL26523520 | 0.86 | CYP1A2 (0.47) | ACP3EPHX1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL8843830 | 0.86 | EPHX1 (0.51) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208166-A1 | Tao Kinase Modulators And Method Of Use | EXELIXIS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208166-A1 | Tao Kinase Modulators And Method Of Use | TAOK1, TAOK3, MAP3K6 | PDCD1 1163/4885CD274 1505/4885ACP3 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.